However, the results have been inconsistent. In this study, a meta-analysis was performed to assess the association of ALDH2 and ADH1B polymorphisms IWR-1 with CRC risk. Methods: Relevant studies were identified from PubMed, Web of Science and CNKI up to February 1st, 2013. Pooled odds ratio (OR) with 95% confidence interval (CI) was calculated using fixed- or random-effects model. Results: A total of 11 case-control studies were selected.

Of which, 11 studies with 2893 cases and 3817 controls concerning ALDH2 Glu487Lys polymorphism, 6 studies with 1864 cases and 3502 controls concerning ADH1B polymorphism. The results indicated that there was a statistically significant link between ALDH2 polymorphism and CRC risk (Glu/Lys + Lys/Lys vs. Glu/Glu: OR = 0.87, 95%CI: 0.78–0.96, P = 0.10; Glu/Lys vs. Glu/Glu: OR = 0.87, 95%CI: 0.77–0.97, P = 0.38) Conclusion: This meta-analysis demonstrates that ALDH2 polymorphism, but not ADH1B, could significantly increase the risk of CRC in East Asians. Key Word(s): 1. ALDH2; ADH1B;; 2. Polymorphism;; 3. Colorectal cancer;; 4. Meta-analysis; Presenting Author: SHAN FAP LIEW Additional Authors: TIING LEONG ANG, ENG KIONG TEO, KWONG MING FOCK Corresponding Author: SHAN FAP LIEW Affiliations: Associate Consultant; Senior Consultant Objective: Patients with severe acute pancreatitis has high suspicion for concomitant common bile duct (CBD) stones if there is presence of either raised

serum bilirubin or dilated CBD. At presentation, CBD stones may have been passed out. Endoscopic FK228 cell line retrograde cholangiopancreatography (ERCP) has been recommended for such high risk patients in the context when cross sectional imaging is negative for CBD stones. Endosonography (EUS) can obviate the need for ERCP since spontaneous passage of CBD stones may occur. Furthermore, the risk for ERCP complications is much higher than EUS. The aim of the study is to evaluate the role of EUS in avoiding diagnostic ERCP in patients

with severe acute pancreatitis with negative cross-sectional imaging but high clinical suspicion of CBD stones. Methods: From the hospital prospective EUS registry, patients with severe acute pancreatitis (as defined by Atlanta Symposium criteria) who underwent EUS were identified from March 2010 to August 2012 retrospectively. Patients with high clinical medchemexpress suspicion (i.e. raised serum bilirubin or dilated CBD or both) but negative cross-sectional imaging for CBD stone were selected. The primary outcome was the avoidance of diagnostic ERCP. Results: A total of 31 patients with severe acute pancreatitis were identified as having high suspicion for CBD stones and enrolled. EUS showed CBD stones in 12 patients (38.7%) and no CBD stone in 19 patients (61.3%). Diagnostic ERCP was avoided in 61.3% while therapeutic ERCP was performed for the rest. All cases of CBD stones identified by EUS were confirmed by ERCP during the same setting (100% specificity).